What Patients Should Discuss with Their Doctor About Tysabri and PML

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Principles to Specific Risk Assessment

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare brain infection is a serious concern that requires careful discussion with your healthcare provider. The legacy of medical research has established a clear link between Tysabri and PML, and understanding this connection is essential for informed decision-making. This page outlines the key facts about PML risk, monitoring, and long-term outlook to support your conversations with clinicians.

The Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has mandated a boxed warning for Tysabri, highlighting that the drug increases the risk of PML. The warning states that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Trial Evidence and Mechanistic Plausibility

Clinical trial data provide evidence of the causal link between Tysabri and PML. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases demonstrate that PML can occur both in the context of combination therapy and as monotherapy, and that the timeline from exposure to harm can vary, with cases reported after as few as eight doses or after longer treatment durations. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of immune cells across the blood-brain barrier. This immunosuppressive effect in the central nervous system can allow reactivation of latent JCV, leading to PML. The risk is particularly elevated in patients with prior immunosuppressant use, as this further compromises immune surveillance.

Regulatory Warnings and Ongoing Risk

Regarding the adequacy of warnings, the FDA has required a boxed warning and a restricted distribution program. The label explicitly states that Tysabri increases the risk of PML and lists the known risk factors. Healthcare professionals are instructed to monitor patients and withhold dosing at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, despite these warnings, PML remains a serious adverse event that can occur even with appropriate monitoring. For affected patients, causation considerations include the presence of anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. The timeline between exposure and documented harm can range from months to years, with cases reported after relatively short exposure (eight doses) and after longer treatment (median 120 weeks). In summary, the evidence establishes a clear causal relationship between Tysabri and PML, supported by clinical trial data, mechanistic plausibility, and regulatory warnings. The risk is stratified by identifiable factors, and the drug's labeling includes specific guidance for risk mitigation. However, the occurrence of PML despite these measures underscores the need for ongoing vigilance in patients receiving Tysabri.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the causal link between Tysabri and Progressive Multifocal Leukoencephalopathy?

Tysabri (natalizumab) is associated with a significantly increased risk of PML, an opportunistic brain infection caused by the JC virus. Clinical trials have documented PML cases in patients receiving Tysabri, and the FDA has issued a boxed warning. The mechanism involves Tysabri's immunosuppressive effect in the central nervous system, which can reactivate latent JCV (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How should healthcare professionals monitor for PML in Tysabri-treated patients?

Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri dosing immediately at the first indication. Tysabri is available only through the TOUCH Prescribing Program to ensure appropriate monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.